Article

No impact of COVID-19 pandemic on prevalence of depressive symptoms in patients with PsA


 

Key clinical point: COVID-19 pandemic did not increase the occurrence of depressive symptoms among patients with psoriatic arthritis (PsA) compared with the period before the pandemic.

Major finding: Majority of patients did not have indications of depressive symptoms during (85.39%) and prior to (83.15%) the pandemic, with 14.61% and 16.85% of patients showing depressive symptoms during and prior to the pandemic, respectively. The prevalence of depressive symptoms was not significantly different before and during the pandemic ( P = .803), irrespective of disease activity.

Study details: Findings are from a longitudinal study including 89 patients with PsA from a National Patient Register in Germany .

Disclosures: This study was funded by the German RheumaDatenRhePort Registry (RHADAR GbR). Most of the authors including the lead author declared being members, receiving honoraria, research support, or remuneration from various sources, including RHADAR Gbr.

Source: Engelbrecht M et al. Front Med. 2021(Nov 1). Doi: 10.3389/fmed.2021.748262.

Recommended Reading

Risankizumab outperforms placebo at 6 months for psoriatic arthritis
Psoriatic Arthritis ICYMI
Psoriatic arthritis and axial spondyloarthritis patients succeed with reduced TNF inhibitor dosing
Psoriatic Arthritis ICYMI
Tofacitinib postmarketing trial data shed light on JAK inhibitor risks
Psoriatic Arthritis ICYMI
Serious infection hospitalizations have declined in patients with PsA
Psoriatic Arthritis ICYMI
PsA: Long-term benefits of upadacitinib in patients with inadequate response to biologics
Psoriatic Arthritis ICYMI
Risk for serious infection lower in patients with PsA vs. RA treated with TNF inhibitors
Psoriatic Arthritis ICYMI
Swollen joints better predict ultrasound-defined inflammation in PsA than tender joints
Psoriatic Arthritis ICYMI
Women with PsA at risk for adverse pregnancy outcomes
Psoriatic Arthritis ICYMI
Guselkumab shows long-term safety and efficacy in biologic-naive patients with PsA
Psoriatic Arthritis ICYMI
PsA: Ixekizumab more effective than adalimumab irrespective of concomitant psoriasis severity
Psoriatic Arthritis ICYMI